

Title (en)  
METHODS AND COMPOUNDS FOR THE TREATING NEUROLOGIC OR NEUROPSYCHIATRIC DISORDERS AND IDENTIFYING COMPOUNDS TO TREAT THE SAME

Title (de)  
METHODEN UND VERBINDUNGEN ZUR BEHANDLUNG VON NEUROLOGISCHEN UND NEUROPSYCHIATRISCHEN ERKRANKUNGEN UND ZUR IDENTIFIZIERUNG VON VERBINDUNGEN ZUR BEHANDLUNG DERSELBEN

Title (fr)  
METHODES ET COMPOSES POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES OU NEUROPSYCHIATRIQUES, ET PROCEDES RELATIFS A L'IDENTIFICATION DE COMPOSES VISANT A TRAITER CES TROUBLES

Publication  
**EP 1385520 A4 20070321 (EN)**

Application  
**EP 02709437 A 20020208**

Priority  

- US 0203876 W 20020208
- US 26731001 P 20010208

Abstract (en)  
[origin: WO02062963A2] A method of treating a neurologic or neuropsychiatric disorder or disease in a mammal is provided. The method comprises administering a fatty acid amide hydrolase inhibitor in an amount sufficient to inhibit deamidation of a fatty acid amide. A method of identifying a fatty acid amide hydrolase inhibitor useful in the treatment of a neurologic or neuropsychiatric disorder is also provided. A method of identifying a fatty acid amide or fatty acid useful in the treatment of a neurologic or neuropsychiatric disorder is also provided.

IPC 1-7  
**A61K 31/185; A61K 31/495; A61K 31/121; A61P 25/00**

IPC 8 full level  
**A61K 31/10** (2006.01); **A61K 31/121** (2006.01); **A61K 31/185** (2006.01); **A61K 31/22** (2006.01); **A61K 31/495** (2006.01); **C12Q 1/34** (2006.01)

CPC (source: EP)  
**A61K 31/10** (2013.01); **A61K 31/121** (2013.01); **A61K 31/185** (2013.01); **A61K 31/22** (2013.01); **A61K 31/495** (2013.01); **A61P 25/00** (2017.12); **C12Q 1/34** (2013.01); **G01N 2500/02** (2013.01)

Citation (search report)  

- [X] US 5688825 A 19971118 - MAKRIYANNIS ALEXANDROS [US], et al
- [X] US 5856537 A 19990105 - LERNER RICHARD A [US], et al
- [Y] US 5618955 A 19970408 - MECHOULAM RAPHAEL [IL], et al
- [Y] WO 9808498 A1 19980305 - NPS PHARMA INC [US], et al
- [Y] GIFFORD ANDREW N ET AL: "Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374)", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 383, no. 1, 21 October 1999 (1999-10-21), pages 9 - 14, XP002417440, ISSN: 0014-2999
- [Y] DEUTSCH D G ET AL: "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 231, no. 1, 1997, pages 217 - 221, XP002417441, ISSN: 0006-291X
- [Y] BOGER D L ET AL: "Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 10, 9 May 2000 (2000-05-09), pages 5044 - 5049, XP002978614, ISSN: 0027-8424
- [X] BRADY B L: "THE ACYLAMIDE AMIDO HYDROLASE OF CANDIDA-UTILIS PURIFICATION AND PROPERTIES", JOURNAL OF GENERAL MICROBIOLOGY, vol. 59, no. PART 1, 1969, pages 47 - 55, XP009078089, ISSN: 0022-1287
- See references of WO 02062963A2

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)  
AL LT LV MK RO SI

DOCDB simple family (publication)  
**WO 02062963 A2 20020815; WO 02062963 A3 20021031; AU 2002243920 A1 20020819; CA 2437353 A1 20020815; EP 1385520 A2 20040204; EP 1385520 A4 20070321**

DOCDB simple family (application)  
**US 0203876 W 20020208; AU 2002243920 A 20020208; CA 2437353 A 20020208; EP 02709437 A 20020208**